Literature DB >> 29510325

Could antiretrovirals be treating EBV in MS? A case report.

Natalia C Drosu1, Elazer R Edelman2, David E Housman3.   

Abstract

We present the case of an HIV-negative patient clinically diagnosed with relapsing-remitting MS who achieved significant disease improvement on Combivir (zidovudine/lamivudine). Within months of treatment, the patient reported complete resolution of previously unremitting fatigue and paresthesiae, with simultaneous improvements in lesion burden detected by MRI. All improvements have been sustained for more than three years. This response may be related to the action of zidovudine as a known inhibitor of EBV lytic DNA replication, suggesting future directions for clinical investigation.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epstein-Barr virus; Multiple sclerosis

Mesh:

Substances:

Year:  2018        PMID: 29510325      PMCID: PMC6100748          DOI: 10.1016/j.msard.2018.02.029

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  7 in total

1.  Could antiretroviral drugs be effective in multiple sclerosis? A case report.

Authors:  H Maruszak; B J Brew; G Giovannoni; J Gold
Journal:  Eur J Neurol       Date:  2011-09       Impact factor: 6.089

2.  Multiple sclerosis remission following antiretroviral therapy in an HIV-infected man.

Authors:  Joshua Chalkley; Joseph R Berger
Journal:  J Neurovirol       Date:  2014-11-01       Impact factor: 2.643

3.  A randomized clinical trial of valacyclovir in multiple sclerosis.

Authors:  J E Friedman; J B Zabriskie; C Plank; D Ablashi; J Whitman; B Shahan; R Edgell; M Shieh; O Rapalino; R Zimmerman; D Sheng
Journal:  Mult Scler       Date:  2005-06       Impact factor: 6.312

4.  Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study.

Authors:  J Andersson; S Britton; I Ernberg; U Andersson; W Henle; B Sköldenberg; A Tisell
Journal:  J Infect Dis       Date:  1986-02       Impact factor: 5.226

Review 5.  The initiation and prevention of multiple sclerosis.

Authors:  Alberto Ascherio; Kassandra L Munger; Jan D Lünemann
Journal:  Nat Rev Neurol       Date:  2012-10-09       Impact factor: 42.937

6.  Anti-human immunodeficiency virus agent 3'-azido-3'-deoxythymidine inhibits replication of Epstein-Barr virus.

Authors:  J C Lin; Z X Zhang; M C Smith; K Biron; J S Pagano
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

Review 7.  Multiple Sclerosis and Subsequent Human Immunodeficiency Virus Infection: A Case with the Rare Comorbidity, Focus on Novel Treatment Issues and Review of the Literature.

Authors:  Charalampos Skarlis; Maria Gontika; Serafeim Katsavos; Giorgios Velonakis; Panagiotis Toulas; Maria Anagnostouli
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

  7 in total
  8 in total

1.  HIV infection and multiple sclerosis: a case with unexpected "no evidence of disease activity" status.

Authors:  Fernando Labella; Fernando Acebrón; María Del Carmen Blanco-Valero; Alba Rodrígez-Martín; Ángela Monterde Ortega; Eduardo Agüera Morales
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

Review 2.  The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis.

Authors:  Caterina Veroni; Francesca Aloisi
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

Review 3.  Epstein-Barr Virus and miRNAs: Partners in Crime in the Pathogenesis of Multiple Sclerosis?

Authors:  Asma Hassani; Gulfaraz Khan
Journal:  Front Immunol       Date:  2019-04-03       Impact factor: 7.561

4.  Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism.

Authors:  Barbara Serafini; Barbara Rosicarelli; Caterina Veroni; Gina Adriana Mazzola; Francesca Aloisi
Journal:  J Virol       Date:  2019-11-26       Impact factor: 5.103

Review 5.  Human immunodeficiency virus and multiple sclerosis: a review of the literature.

Authors:  Maria-Ioanna Stefanou; Markus Krumbholz; Ulf Ziemann; Markus C Kowarik
Journal:  Neurol Res Pract       Date:  2019-08-20

6.  Evaluation of IL-1β and IL-6 Expression following EBNA-1 and BRLF-1 Peptide Treatment in Epstein-Barr Virus-Positive Multiple Sclerosis Patients.

Authors:  Roya Kianfar; Mehrdad Ravanshad; Mohammad Adel Ghiass; Nastaran Rafiee; Ali Shayeghpour; Ali Maleki
Journal:  Intervirology       Date:  2022-02-14       Impact factor: 2.294

Review 7.  Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies.

Authors:  Amit Bar-Or; Michael P Pender; Rajiv Khanna; Lawrence Steinman; Hans-Peter Hartung; Tap Maniar; Ed Croze; Blake T Aftab; Gavin Giovannoni; Manher A Joshi
Journal:  Trends Mol Med       Date:  2019-12-17       Impact factor: 11.951

Review 8.  Cytomegalovirus and Epstein-Barr Virus Associations with Neurological Diseases and the Need for Vaccine Development.

Authors:  Peter A C Maple
Journal:  Vaccines (Basel)       Date:  2020-01-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.